Letters to the Editor
Tisseel Duo 500
- Peter van Gaalen
- Aust Prescr 2003;26:75-7
- 1 August 2003
- DOI: 10.18773/austprescr.2003.057
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – I wish to draw your attention to some inaccuracy in the new drug comment about Tisseel Duo 500 (Aust Prescr 2003;26:46).
The article commenced by correctly referring to Tisseel Duo 500 with regard to available sizes and approved indications. It then refers to the composition of the 'kit', referring to vials of thrombin, calcium chloride, fibrinolysis inhibitor etc. This description refers to the lyophilised kit form of Tisseel which required reconstitution. The kit was previously available in Australia under the Special Access Scheme of the Therapeutic Goods Administration, until the registered Tisseel Duo 500 became available. This kit was only viable for four hours following reconstitution. It is no longer available in Australia.
Tisseel Duo 500 is deep frozen fibrin sealant, in a preloaded double syringe delivered with the same Duploject device. It does not require reconstitution, only thawing and warming to 37oC. Once thawed, Tisseel Duo 500 is viable for 48 hours. The thawing process requires very little time once removed from the freezer, significantly less than an autologous cryoprecipitate preparation process.
With regards to viral safety, I can state that the previous formulation of the product has been used for 25 years in 50 countries around the world in over 8 million applications resulting in no reported transmissions of HIV, Hepatitis B or C and prion disease. This is due to the donor screening program, the double steam heat treated processing and PCR testing of the product during the manufacturing process.
There are numerous published articles about fibrin sealants available from our Medical Affairs department.
Peter van Gaalen
Bio Surgery Manager
Bio Surgery Manager , Baxter Healthcare Toongabbie, NSW